top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Aug 22, 2023
What is the purpose of registration submission guide, based on data from scientific literature?
Apr 7, 2022
The economic impact of the new health technologies
Feb 9, 2021
Unraveling the Abbreviated Development Path
Feb 9, 2021
What are the new expectations for the development of incremental products and medicines?
Feb 9, 2021
COVID-19: What facilities is ANVISA providing at this time of crisis?
Feb 9, 2021
API, BPF and drug dossier - How to align the processes to ensure success in registration?
Feb 9, 2021
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
Feb 9, 2021
Publication of the new API regulatory framework: what is essential to know?
Feb 9, 2021
What is important about the new regulatory framework for good manufacturing practices?
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
